Strategic Goal
Position BIEL + Electrome as the first publicly traded AI‑powered bioelectronic pain‑modulation platform — and use a rising PPS as the engine that accelerates financing, adoption, and acquisition interest.
1. Formalize a High‑Visibility Licensing Partnership
A rising PPS unlocks financing, investor attention, and strategic interest.
But none of that happens without clarity.
Action
Announce a formal licensing + commercialization agreement where:
BIEL provides:
ActiPatch hardware
Manufacturing
Regulatory submissions
Legacy clinical data
Real‑world usage data
Electrome provides:
AI algorithms
Digital‑twin modeling
Predictive pain analytics
App ecosystem
Commercialization strategy
Structure:
BIEL retains IP ownership
Electrome receives exclusive commercialization rights in defined markets
BIEL earns manufacturing margin + royalties
Electrome earns AI‑platform revenue + subscription layers
Why this boosts PPS:
Investors reward clarity and forward momentum.
A formal partnership eliminates uncertainty and signals a scalable business model.
2. Re‑Submit a Clean, Unified 510(k) With an AI‑Forward Narrative
Action
BIEL + Electrome jointly:
Hire a specialized 510(k) consulting firm
Clarify whether clinical data is required
Submit a complete, compliant application
Publish a regulatory roadmap for investors
Narrative
“ActiPatch Gen‑2: AI‑enhanced bioelectronic therapy with adaptive algorithms.”
Why this boosts PPS:
Regulatory clarity is one of the strongest catalysts for microcap med‑tech stocks.
3. Launch ActiPatch Gen‑2 as an AI‑Powered Wearable
Frames Electrome as an AI platform capable of:
digital‑twin modeling
adaptive therapy
predictive pain forecasting
This is exactly the type of narrative that earns premium valuations.
Action
Develop ActiPatch Gen‑2, featuring:
Updated waveform
Improved battery life
Better adhesive
Bluetooth connectivity
Electrome AI app integration
Personalized therapy loops
Why this boosts PPS:
A modernized product + AI integration = a story investors understand and chase.
4. Build the “Bioelectric AI Data Flywheel”
AI companies are valued on data, not revenue.
Action
Create a data‑driven ecosystem:
Every ActiPatch Gen‑2 device streams anonymized usage data
Electrome’s AI learns from millions of data points
Predictive pain models improve over time
Personalized therapy becomes more effective
Better outcomes = more adoption = more data
Why this boosts PPS:
A defensible data moat is the core ingredient behind every major AI valuation.
5. Position BIEL as the Only Public Gateway to Bioelectric AI
Public investors have been shut out of early AI wealth creation.
Action
Frame BIEL as:
“The first publicly traded AI‑powered bioelectronic therapy platform.”
Why this boosts PPS
Investors are desperate for AI exposure.
BIEL becomes a rare, accessible entry point.
6. Launch a Coordinated Investor‑Facing AI Narrative
The post lays out the exact narrative investors respond to:
AI
Bioelectronic medicine
Predictive health
Wearables
GLP‑1‑adjacent wellness
Consumer health
Action
Release a series of investor‑focused communications:
Partnership announcement
AI integration roadmap
Data‑flywheel explanation
ActiPatch Gen‑2 teaser
Regulatory timeline
Market opportunity breakdown
Why this boosts PPS
Narrative drives attention.
Attention drives buying.
Buying drives PPS.
7. Use a Rising PPS to Secure Non‑Dilutive Financing
A higher PPS unlocks:
cheaper capital
better terms
institutional interest
strategic partnerships
Action
Once PPS rises:
Secure non‑dilutive credit facilities
Pursue strategic co‑development deals
Expand manufacturing
Accelerate AI development
Fund retail expansion
Why this boosts PPS
Growth‑mode financing replaces survival‑mode financing.
8. Align Ken Mayer’s Incentives With PPS Growth
The post frames Mayer as a key execution leader.
Action
Tie Mayer’s compensation to:
revenue milestones
regulatory milestones
AI integration milestones
PPS thresholds
partnership expansion
Why this boosts PPS
Aligned incentives reduce investor fear and increase confidence in leadership.
9. Prepare for Strategic Buyer Interest Realistic Potential Acquirers:
J&J
Haleon
Philips
Medtronic
Abbott
Garmin
Oura
Hims & Hers
Noom
Action
Build a data room with:
AI models
usage data
clinical outcomes
manufacturing capacity
regulatory progress
partnership agreements
Why this boosts PPS:
Strategic buyers pay for momentum, not potential.
A rising PPS signals momentum.
10. The Strategy in One Line
Turn BIEL + Electrome into the world’s first AI‑powered bioelectric pain‑modulation platform — and use a rising PPS as the engine that accelerates financing, adoption, and acquisition interest to the benefit of BIEL and Ken Mayer’s leadership vision.
Position BIEL + Electrome as the first publicly traded AI‑powered bioelectronic pain‑modulation platform — and use a rising PPS as the engine that accelerates financing, adoption, and acquisition interest.
1. Formalize a High‑Visibility Licensing Partnership
A rising PPS unlocks financing, investor attention, and strategic interest.
But none of that happens without clarity.
Action
Announce a formal licensing + commercialization agreement where:
BIEL provides:
ActiPatch hardware
Manufacturing
Regulatory submissions
Legacy clinical data
Real‑world usage data
Electrome provides:
AI algorithms
Digital‑twin modeling
Predictive pain analytics
App ecosystem
Commercialization strategy
Structure:
BIEL retains IP ownership
Electrome receives exclusive commercialization rights in defined markets
BIEL earns manufacturing margin + royalties
Electrome earns AI‑platform revenue + subscription layers
Why this boosts PPS:
Investors reward clarity and forward momentum.
A formal partnership eliminates uncertainty and signals a scalable business model.
2. Re‑Submit a Clean, Unified 510(k) With an AI‑Forward Narrative
Action
BIEL + Electrome jointly:
Hire a specialized 510(k) consulting firm
Clarify whether clinical data is required
Submit a complete, compliant application
Publish a regulatory roadmap for investors
Narrative
“ActiPatch Gen‑2: AI‑enhanced bioelectronic therapy with adaptive algorithms.”
Why this boosts PPS:
Regulatory clarity is one of the strongest catalysts for microcap med‑tech stocks.
3. Launch ActiPatch Gen‑2 as an AI‑Powered Wearable
Frames Electrome as an AI platform capable of:
digital‑twin modeling
adaptive therapy
predictive pain forecasting
This is exactly the type of narrative that earns premium valuations.
Action
Develop ActiPatch Gen‑2, featuring:
Updated waveform
Improved battery life
Better adhesive
Bluetooth connectivity
Electrome AI app integration
Personalized therapy loops
Why this boosts PPS:
A modernized product + AI integration = a story investors understand and chase.
4. Build the “Bioelectric AI Data Flywheel”
AI companies are valued on data, not revenue.
Action
Create a data‑driven ecosystem:
Every ActiPatch Gen‑2 device streams anonymized usage data
Electrome’s AI learns from millions of data points
Predictive pain models improve over time
Personalized therapy becomes more effective
Better outcomes = more adoption = more data
Why this boosts PPS:
A defensible data moat is the core ingredient behind every major AI valuation.
5. Position BIEL as the Only Public Gateway to Bioelectric AI
Public investors have been shut out of early AI wealth creation.
Action
Frame BIEL as:
“The first publicly traded AI‑powered bioelectronic therapy platform.”
Why this boosts PPS
Investors are desperate for AI exposure.
BIEL becomes a rare, accessible entry point.
6. Launch a Coordinated Investor‑Facing AI Narrative
The post lays out the exact narrative investors respond to:
AI
Bioelectronic medicine
Predictive health
Wearables
GLP‑1‑adjacent wellness
Consumer health
Action
Release a series of investor‑focused communications:
Partnership announcement
AI integration roadmap
Data‑flywheel explanation
ActiPatch Gen‑2 teaser
Regulatory timeline
Market opportunity breakdown
Why this boosts PPS
Narrative drives attention.
Attention drives buying.
Buying drives PPS.
7. Use a Rising PPS to Secure Non‑Dilutive Financing
A higher PPS unlocks:
cheaper capital
better terms
institutional interest
strategic partnerships
Action
Once PPS rises:
Secure non‑dilutive credit facilities
Pursue strategic co‑development deals
Expand manufacturing
Accelerate AI development
Fund retail expansion
Why this boosts PPS
Growth‑mode financing replaces survival‑mode financing.
8. Align Ken Mayer’s Incentives With PPS Growth
The post frames Mayer as a key execution leader.
Action
Tie Mayer’s compensation to:
revenue milestones
regulatory milestones
AI integration milestones
PPS thresholds
partnership expansion
Why this boosts PPS
Aligned incentives reduce investor fear and increase confidence in leadership.
9. Prepare for Strategic Buyer Interest Realistic Potential Acquirers:
J&J
Haleon
Philips
Medtronic
Abbott
Garmin
Oura
Hims & Hers
Noom
Action
Build a data room with:
AI models
usage data
clinical outcomes
manufacturing capacity
regulatory progress
partnership agreements
Why this boosts PPS:
Strategic buyers pay for momentum, not potential.
A rising PPS signals momentum.
10. The Strategy in One Line
Turn BIEL + Electrome into the world’s first AI‑powered bioelectric pain‑modulation platform — and use a rising PPS as the engine that accelerates financing, adoption, and acquisition interest to the benefit of BIEL and Ken Mayer’s leadership vision.
